Jeffrey S. Weber, MD, PhD

Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events (AEs) commonly associated with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in the adjuvant setting for patients with

V600E or V600K&ndash;positive stage III melanoma.

According to Weber, the AEs are very similar to those found with the combination in patients with metastatic disease. However, fatigue and fevers are the most difficult to deal with after receiving this combination. Weber says these 2 particular AEs have led to a number of discontinuations of the treatment as it can be debilitating to the patient.

Videos

Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events commonly associated with the combination of dabrafenib and trametinib in the adjuvant setting for patients with BRAF V600E&ndash; or V600K&ndash;positive stage III melanoma.

Adverse Events With Dabrafenib/Trametinib Combination in Melanoma

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center,

Nivolumab in the Adjuvant Setting for Melanoma

Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses how results of the CheckMate-238 study will impact patients with melanoma.

Impact of CheckMate-238 Results for Patients With Melanoma

Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for

Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for <em>BRAF</em>-mutant melanoma.

Future Combination Strategies for BRAF-Mutant Melanoma

Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.

Articles

Toxicity of Immunotherapies in Melanoma

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a Specialized Programs of Research Excellence (SPORE) grant.

A Specialized Programs of Research Excellence (SPORE) grant is given out by the NCI

SPORE grants bring together investigators from all different disciplines focused on one histology

As a part of the SPORE grant given to Moffitt Cancer Center, each project has preclinical laboratory pieces leading to a clinical trial

Two out of three SPORE projects at Moffitt currently have clinical trials ongoing

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a SPORE grant.